Kangmei Pharmaceutical Co (SHSE:600518) Tariff Resilience Score: 0/10 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600518 Kangmei Pharmaceutical Co Ltd SHSE:600518
51 GF Score
Price ¥1.36
GF Value ¥1.47
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kangmei Pharmaceutical Co Tariff Resilience Score?

Kangmei Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Kangmei Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kangmei Pharmaceutical Co might have .

Kangmei Pharmaceutical Co  (SHSE:600518) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kangmei Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:600518
51GF Score
Kangmei Pharmaceutical Co Ltd SHSE:600518
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kangmei Pharmaceutical Co (SHSE:600518) Overvalued in 2026?

Based on GuruFocus' analysis, Kangmei Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥1.36 is trading 7.5% below its estimated GF Value™ of ¥1.47. GuruFocus considers Kangmei Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600518:

  • Tariff Resilience Score: 0
  • GF Value™: ¥1.47 vs. price of ¥1.36 (7.5% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kangmei Pharmaceutical Co Business Description

Address Taike Road, Xiameilin, Futian District, Guangdong, Shenzhen, CHN, 518000
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.
51GF Score

Get the complete analysis for SHSE:600518

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥1.36
Price
¥1.47
GF Value